In recent years, metronomic chemotherapy, consisting of continuous administration of low doses of cytotoxic agents, has being used as rescue therapy for different tumours. The aim of this study was to retrospectively assess the efficacy and safety of low-dose metronomic, oral capecitabine in pretreated or frail patients with recurrent upper gastrointestinal tract cancer. Patients with pretreated upper gastrointestinal tract cancer or who were not candidates for standard chemotherapy because of toxicity concerns received capecitabine at 1500 mg per day continuously until disease progression or occurrence of toxicity. Forty-seven patients (25 oesophagogastric cancer, 22 pancreatobiliary cancer; 25 men, 22 women; median age 69 years, range 42-90) were included in the study. Forty-five percent of the patients had received at least two previous lines of treatment and the median number of previous treatments was 1 (range 0-5). Twelve (31.6%) patients achieved clinical benefit (one partial response, 11 stable disease), whereas nine (23.7%) patients were progression free for at least 6 months. In an exploratory analysis, there was a significant relationship between performance status and clinical benefit (hazard ratio = 8.25; P = 0.01). The median overall survival was 5 months. A good performance status was associated with a longer survival (hazard ratio = 0.26; P < 0.01). No severe toxicity or treatment-related death was reported. Metronomic capecitabine showed good safety and moderate activity in frail or pretreated patients with advanced, upper gastrointestinal tract cancer.
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Introduction
The prognosis of progressive upper gastrointestinal tract cancer after first-line treatment is slowly improving and the median survival is now reported to be up to 9 months. Nonetheless, the role of rescue chemotherapy remains debatable. Indeed, the majority of data on second-line chemotherapy of oesophagogastric and pancreatobiliary cancer derive from either phase II single-arm or retrospective studies. Although recent phase III trials have reported the benefit of combined chemotherapy [1] [2] [3] [4] [5] or target molecules [6] [7] [8] [9] compared with best supportive care or monochemotherapy, many patients with recurrent, upper, gastrointestinal tract cancer cannot tolerate standard-dose chemotherapy [10] . Thus, the identification of well-tolerated regimens, able to control disease progression and symptomatology, remains the overriding aim of these patients' care. Over the past few years, continuous, low, fixed doses of cytotoxic drugs have been tested in different tumour types, leading to tumour regression and very low toxicity [11] [12] [13] . These particular schedules, known as metronomic chemotherapy (MCT), induced both sustained apoptotic effects by directly or indirectly targeting tumour vascular endothelial cells [14] , and immunomodulatory effects [15] . Few clinical experiences showing clinical benefit in 30-73% of the patients have focused on metronomic schedules in patients with gastrointestinal cancer to date [16] [17] [18] [19] [20] [21] [22] . Accordingly, fluoropyrimidines, which are milestone drugs in the treatment of gastrointestinal tumours, have rarely been tested at metronomic dosage [16, [18] [19] [20] [21] [22] . Hence, we carried out a study aimed at retrospectively evaluating the activity and tolerability of metronomic capecitabine (mCAP) in patients with both advanced pancreatobiliary and oesophagogastric cancers after firstline progression.
Patients and methods
This study enrolled 47 consecutive patients with upper gastrointestinal tract malignancies treated with mCAP at our Institution over a 5-year period. All patients fulfilled the following criteria: histological diagnosis of a gastric, oesophageal, pancreatic or biliary tract carcinoma; progressive disease (PD) at baseline; inability to receive standard chemotherapy because of toxicity concerns or failure of one or more previous chemotherapeutic lines for metastatic disease; age at least 18 years; ECOG performance status (PS) up to 3; life expectancy more than 3 months as assessed clinically; and adequate bone marrow, renal and liver function (leucocyte count ≥ 3000/ mm 3 ; platelet count ≥ 100 000 mm 3 ; creatinine < 2.0 mg/ dl; total bilirubin levels ≤ 1.5 mg/dl; and transaminase values < 3 times normal values). Exclusion criteria were as follows: brain metastases, symptomatic cardiac disease, recent history of myocardial infarction, active infections, inflammatory bowel disease and pregnancy.
All patients received a regimen of capecitabine 1500 mg orally within 30 min after dinner. Treatment was administered continually, without drug-free intervals, until the occurrence of either disease progression or unacceptable toxicity. To facilitate comparison of results, one cycle was arbitrarily defined as 28 days of treatment.
Treatment toxicity was assessed monthly according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 3 (CTCAE version 3, 2006) . Objective response was clinically evaluated every month and using imaging approximately every 2 months. Clinical benefit (CB), which reflected the proportion of patients with complete responses, partial responses (PR) and stable disease (SD), was assessed according to the RECIST criteria. CB and duration of response (DOR), calculated from documentation of complete responses or PR or, when responses consisted in SD, from the beginning of the treatment to documentation of PD, were used to assess the activity of mCAP. All patients provided written informed consent, and protocol approval of the Sant'Andrea Hospital Ethics Committee was obtained (No. 1596/2013).
Statistical analysis
SPSS statistical software, version 22 (SPSS Inc., Chicago, Illinois, USA), was used. The χ 2 -test or Fisher's exact test was used when appropriate. A P value of 0.05 was considered statistically significant. Logistic regression analysis was performed to model the association between CB and clinicopathological parameters. Overall survival (OS) was calculated from the beginning of the treatment till death (for any cause) or until the end of the study follow-up. The analysis of OS was carried out using the Kaplan-Meier method and compared using the log-rank test. Patients were censored at the last observation in cases where death had not occurred. Cox proportional hazards regression was performed to analyse the effect of all clinicopathological variables on OS.
Results
Forty-seven patients with advanced gastrointestinal cancer, 25 patients with oesophagogastric (53%) and 22 patients with pancreatobiliary (47%) were included in the study. The median age of the patients was 69 years (range 42-90). ECOG PS was 0-1 and at least 2 in 46.8 and 53.2% of patients, respectively ( Fig. 1 ). Twenty-one patients (45%) had received at least two previous lines of treatment and the median number of previous treatments was 1 (range 0-5). All patients were assessable for safety. Table 3) . Upon multivariate analysis, which also included age and sex, a good PS was an independent predictor of CB (HR = 10.0; 95% CI: 1.3-78.2; P = 0.03).
Overall survival
All 47 patients treated were assessable for OS, with a median follow-up duration of 5 months (range 1-37). At the time of analysis, there were 43 deaths. The median OS was 5 months (range 1-37; 95% CI: 3.89-6.10 months). The median OS of responding patients was 18 months (range 5-37; 95% CI: 5.28-30.7), whereas the median OS of the nonresponders was 4 months (range 2-12; 95% CI: 3.11-4.89) ( Fig. 2a ). Finally, the median OS of patients with ECOG PS = 0-1 was 10 months (range 2-37; 95% CI: 7.85-12.14), whereas the median OS of patients with PS = 2-3 was 3 months (range 1-17; 95% CI: 1.77-4.22) ( Fig. 2b) .
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Safety
Overall, the incidence of haematologic, gastrointestinal toxicity and hand-foot syndrome was low and the maximum toxicity reported was grade 2 (Table 4 ). Neither grade 3-4 adverse events nor treatment-related deaths were observed. Anaemia was the most common haematologic toxicity. Among adverse events, at univariate analysis, only anaemia was related positively to CB Kaplan-Meier curves of overall survival according to: clinical benefit (CB) (a); ECOG performance status (PS) (b); occurrence of anaemia (c). CI, confidence interval; HR, hazard ratio. (HR = 6.2; 95% CI: 1.22-31.92; P = 0.03). At logistic regression analyses adjusted for sex, age and PS, it remained an independent predictor of CB (P = 0.02). Figure 2c shows OS curves according to the presence of anaemia. In detail, the median OS was 10 months (range 5-37; 95% CI: 7.22-12.77) and 4 months (range 1-34; 95% CI: 3.14-4.85) in patients with and without anaemia, respectively (P = 0.02, log-rank test).
Discussion
Recently, a significant extension of OS was achieved with chemotherapy and target therapy in recurrent, upper gastrointestinal tract cancer. Indeed, compared with 5-fluorouracil alone combination regimens of both oxaliplatin with fluoropyrimidine or nanoliposomal irinotecan with 5-fluorouracil increased OS up to 6 months in patients with gemcitabine-refractory pancreatic cancer [1, 2] . Moreover, in a study that explored the effectiveness of immunotherapy in comparable patients, the use of Cy/GVAX and CRS-207 yielded a similar outcome [23] . Furthermore, also in pretreated patients with gastric cancer compared with active supportive therapy, chemotherapy showed that it could improve OS, which reached 5.3 months [3] [4] [5] . The anti-VEGFR-2 ramucirumab was instead the first biological treatment that showed survival benefits towards best supportive care in patients with advanced oesophagogastric cancer progressing after first-line treatment [7] . Moreover, the combination of ramucirumab with taxanes increased survival even up to 9.6 months [8] . Nonetheless, despite such a remarkable development of new therapy, recurrent, upper gastrointestinal tract cancer still remains incurable. Therefore, in this setting of patients, not only prolonged survival but also control of symptoms and quality of life are the main goals of treatment.
In this study, we aimed to retrospectively evaluate the outcome of mCAP in pretreated or frail patients with cancer of the upper gastrointestinal tract.
MCT is being considered a kind of multitarget cancer therapy rather than an exclusive antiangiogenic therapy [13] . Indeed, several studies have shown that MCT determines significant immunomodulatory effects, such as the depletion of Tregs within the tumour microenvironment [24, 25] . Moreover, a number of additional mechanisms have also been identified, including the reduction of cancer cell stemness [26] or the selective inhibition of HIF-1α [27] . Although studies on metronomics have increased in the past few years, only a few have reported results on metronomic schedules of oral fluoropirimidines in upper gastrointestinal cancer [16,18 -21] . In these studies, metronomic fluoropyrimidines were variously associated with antiproliferative and/or anti-inflammatory drugs [16, 18] determining CB in up to 45% of the patients.
We reported a CB of 31.6% in pretreated patients with cancer of the upper gastrointestinal tract using continuative low doses of capecitabine. Our findings were consistent with the kind of the patients included and the literature data [16, 18] . However, in a recent study, a higher rate of SD was reported in a comparable patients' setting, but the number of patients included was quite small [21] . Our study showed no difference in the treatment activity between pancreatobiliary and oesophagogastric tumours. Interestingly, ECOG PS was shown to be the only clinicopathologic variable related to CB, suggesting that patients with a good PS (≤ 1) should be ordinarily considered for treatment after disease recurrence. Although the benefit was undeniably moderate, for only a third of the patient, it was, however, related to a survival advantage.
A favourable toxicity profile of mCAP, without incidence of severe adverse events, was a major finding of our study. The most common toxicity was anaemia, which was present in 19% of the patients. As reported previously [20, 28] , also in our study, the occurrence of anaemia was a positive prognostic factor for survival. Accordingly, macrocytosis has also been inversely related to the risk of disease progression in patients treated with mCAP plus cyclophosphamide and bevacizumab for metastatic breast cancer [29] . This finding could be attributed to thymidylate synthase inhibition by capecitabine. Moreover, our data are consistent with the majority of former studies proving the good tolerability of MCT with a low occurrence of severe toxicity [22] . Recently, a relationship between the incidence of haematologic toxicity and some gene polymorphisms was also described in patients treated with either standard [30] or low-dose capecitabine [31] , possibly enabling better patients' selection.
In conclusion, our study candidates mCAP as salvage chemotherapy for heavily pretreated or frail patients with upper gastrointestinal cancer, holding a good PS. Its good toxicity profile and easy, oral administration fosters further prospective studies to confirm these preliminary results and test combination regimens with other cytotoxic and/or target molecules.
